1034148-04-3

Basic information

• Product Name: AZD5423
• Synonyms: AZD5423;2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide
• CAS NO: 1034148-04-3
• Molecular Formula: C₂₅H₂₁F₄N₃O₃
• Molecular Weight: 487.4461528
• Mol File: 1034148-04-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AZD5423(CAS DataBase Reference)
• NIST Chemistry Reference: AZD5423(1034148-04-3)
• EPA Substance Registry System: AZD5423(1034148-04-3)

Safety Data

• Hazardous Substances Data: 1034148-04-3(Hazardous Substances Data)

Usage

General Description

AZD5423 is a potent and selective non-steroidal glucocorticoid receptor modulator (SGRM) developed for the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The compound has high affinity and selectivity for the glucocorticoid receptor, with reduced systemic exposure and metabolic activation compared to traditional glucocorticoids. AZD5423 has shown promising results in preclinical studies, with potent anti-inflammatory effects and a favorable safety profile. It has the potential to offer improved therapeutic benefits and reduced side effects compared to traditional glucocorticoid therapies, making it a promising candidate for the treatment of inflammatory diseases.

Upstream product

• 1034153-23-5 (1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)propan-2-amine 
• 407-25-0 trifluoroacetic anhydride 
• 383-63-1 ethyl trifluoroacetate, 
• 1417334-58-7 (1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-amine hydrochloride 

Downstream Products

• 1034148-48-5 2,2,2-trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-hydroxyphenyl)propan-2-yl)acetamide 

Relevant articles and documents

Self-assembled asymmetric catalyst engaged in a continuous-flow platform: An anti -selective catalytic asymmetric nitroaldol reaction

An anti-selective catalytic asymmetric nitroaldol reaction was manifested in a continuous-flow platform. The requisite Nd/Na heterogeneous catalyst was readily prepared by self-assembly of an amide-based chiral ligand, NdO 1/5(OiPr)13/5, NaHMDS, and a multiwalled carbon nanotube without covalent linkage. A stainless-steel column filled with the Nd/Na catalyst was incorporated in a flow system to promote the nitroaldol reaction with high stereoselectivity. The flow system with the heterogeneous catalyst obviated the quenching operation, and the cooling system was minimized.

CRYSTALLINE FORM OF INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS

Crystalline forms of 2,2,2-trifluoro-N-[(lR,2S)-l-[l-(4-fluorophenyl)in- dazol-5-yl]oxy-l-(3-methoxyphenyl)propan-2-yl]acetamide, processes for obtaining them, pharmaceutical intermediates used in their manu? facture, pharmaceutical compositions containing them, and their use in medical treatment.